New Counties Eligible for Third Annual GlaxoSmithKline IMPACT Awards

Up to Ten Triangle-Area Nonprofits Will Receive $40,000 in Time of Great Need; Application Deadline is March 31, 2011

Mar 02, 2011, 16:09 ET from GlaxoSmithKline

DURHAM, N.C., March 2, 2011 /PRNewswire/ -- With North Carolina potentially facing deep cuts in health and human services programs, three new counties are joining the list of those eligible for a GlaxoSmithKline IMPACT Award.  For the third year in a row, GlaxoSmithKline and Triangle Community Foundation will award $40,000 each to up to ten groups that set an outstanding example in providing access to healthcare.  

The third annual GlaxoSmithKline IMPACT Awards will honor community nonprofit organizations in Alamance, Chatham, Durham, Franklin, Harnett, Johnston, Lee, Moore, Orange, Person or Wake counties that excel in providing access to healthcare.   The success of the event in 2009 and 2010 convinced sponsors to extend eligibility to nonprofits in Alamance, Lee, and Moore counties.

Applications will be accepted through Thursday, March 31, 2011 at 4 p.m. EDT.

The GlaxoSmithKline IMPACT Awards (the initials of which stand for  Innovation, Management, Partnership, Achievement, Community focus and Targeting needs within community-based healthcare organizations) honor nonprofit organizations that have a significant impact on their communities and are capable, proactive and effective in their work.  As has been reported, the economic downturn combined with proposed cuts to state budgets underscore the important role of nonprofits in our communities.   

To qualify for a GlaxoSmithKline IMPACT award, an applicant must be located in one of the eligible counties and its primary mission must be to provide access to community healthcare services to residents of the included counties. Each group must have annual total operating expenses between $160,000 and $3 million; and have been in existence as a 501(c)(3) nonprofit organization for at least five years. Organizations will be recognized for the success and achievements of their overall body of work, not for new or specific initiatives.

A panel of local and national healthcare delivery experts and GlaxoSmithKline representatives will determine the winners. Their criteria will include a strong demonstration of ongoing success in providing access to healthcare; commitment to serving people in need; facilitation of healthcare delivery, substantive partnerships; policy development; and a solid record of achievement, management and leadership.

GlaxoSmithKline and Triangle Community Foundation will present the GlaxoSmithKline IMPACT Awards at a ceremony in the Research Triangle Park in late 2011. For more details and to apply, please visit the GlaxoSmithKline site at and select "Our work with communities," then click "Health programs," then click "Awards," and finally click "RTP region." Or call GlaxoSmithKline Community Partnerships at 919-483-2669. To learn about previous winners, please visit

About GlaxoSmithKline

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at   

About Triangle Community Foundation

Triangle Community Foundation is a nonprofit organization that manages $140 million in funds established by individuals, businesses and families. From these funds, we give grants to nonprofit organizations and administer a variety of programs for the community's benefit. The Foundation currently manages over 750 funds, ranging in size from $10,000 to $10 million, primarily for the benefit of Wake, Durham, Orange and Chatham counties. During the 2009-10 fiscal year, the Foundation granted more than $11.5 million to nonprofits, schools and community efforts. On average, we distribute more than 10% of our assets each year, raising the total value of grants made since the Foundation's inception in 1983 to nearly $153 million. For more information, please visit

SOURCE GlaxoSmithKline